References of "COLLETTE, Julien"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailVertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
Collette, Julien ULg; Bruyère, Olivier ULg; Kaufman, J. M. et al

in Osteoporosis International (2010), 21(2), 233-41

Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels ... [more ▼]

Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels of biochemical markers of bone formation and resorption. The vertebral anti-fracture efficacy of strontium ranelate was shown to be independent of baseline bone turnover levels. INTRODUCTION: Bone turnover (BTO) levels vary among women at risk of osteoporotic fracture. Strontium ranelate is an anti-osteoporotic treatment increasing bone formation and reducing bone resorption. It was hypothesised that its anti-fracture efficacy would be independent of baseline BTO levels. METHODS: Post-menopausal women with osteoporosis from two pooled studies were stratified in tertiles according to baseline levels of two BTO markers: bone-specific alkaline phosphatase (b-ALP, n = 4995) and serum C-telopeptide cross-links (sCTX, n = 4891). Vertebral fracture risk was assessed over 3 years with strontium ranelate 2 g/day or placebo. RESULTS: In the placebo group, relative risk of vertebral fractures increased with BTO tertiles by 32% and 24% for patients in the highest tertile for b-ALP and CTX, respectively, compared to those in the lowest tertile. In the strontium ranelate group, incidences of vertebral fracture did not differ significantly across BTO tertiles. Significant reductions in vertebral fractures with strontium ranelate were seen in all tertiles of both markers, with relative risk reductions of 31% to 47% relative to placebo. Risk reduction did not differ among tertiles (b-ALP: p = 0.513; sCTX: p = 0.290). CONCLUSION: The vertebral anti-fracture efficacy of strontium ranelate was independent of baseline BTO levels. Strontium ranelate offers clinical benefits to women across a wide range of metabolic states. [less ▲]

Detailed reference viewed: 60 (22 ULg)
Full Text
Peer Reviewed
See detailRelationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
Bruyère, Olivier ULg; Collette, Julien ULg; Rizzoli, R. et al

in Osteoporosis International (2010), 21

From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were ... [more ▼]

From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were associated with 3-year bone mineral density (BMD) changes, but not fracture incidence in patients treated with strontium ranelate. INTRODUCTION: The purpose of this study was to assess if short-term change in biochemical markers of bone remodelling is associated with long-term BMD change and fracture incidence observed during treatment with strontium ranelate. METHODS: From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) were assessed at baseline and after 3 months. RESULTS: Two thousand three hundred seventy-three women were included in this study. Multiple regression analysis showed that 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I were significantly (p < 0.001) associated with 3-year BMD changes at the lumbar spine and the femoral neck. Changes in s-CTX I, PICP and BALP were significantly associated with change in total proximal femur BMD. Changes in biochemical markers explain less than 8% of the BMD changes. The 3-month changes in BALP, PICP s-CTX I and s-NTX I were not significantly associated with fracture incidence. CONCLUSIONS: Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level. [less ▲]

Detailed reference viewed: 42 (19 ULg)
Full Text
Peer Reviewed
See detailHighest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study.
Bruyère, Olivier ULg; Decock, Caroline; Delhez, Melanie et al

in Women's Health (2009), 5(1), 49-54

The reduced capacity of older skin to synthesize vitamin D(3) under the influence of ultraviolet light makes older persons at risk of vitamin D deficiency. The risk could even be increased in ... [more ▼]

The reduced capacity of older skin to synthesize vitamin D(3) under the influence of ultraviolet light makes older persons at risk of vitamin D deficiency. The risk could even be increased in institutionalized persons owing to their lower sunshine exposure. It has been reported that an inadequate vitamin D level is associated with secondary hyperparathyroidism, increased bone turnover, and bone loss, which increase fracture risk. The objective of this study was to assess the prevalence of inadequate serum vitamin D levels in institutionalized, postmenopausal, osteoporotic women. Assessment of 25-hydroxyvitamin D [25(OH)D] was performed in 445 institutionalized, osteoporotic women from nine countries (Australia, Belgium, France, Germany, Hungary, Italy, Poland, Spain and UK). For each institutionalized woman, three age-matched, noninstitutionalized, osteoporotic controls were also included. Four cutoffs of 25(OH)D inadequacy were fixed: less than 80, less than 75, less than 50 and less than 30 nmol/l. Mean age was 79.7 years (standard deviation [SD] = 5.8) for the institutionalized women and 79.5 years (SD = 5.5) for the noninstitutionalized women (p = 0.45). Significantly fewer institutionalized women received vitamin D supplements (13.2 vs 24.0%; p < 0.0001). In women without vitamin D supplements, the level of 25(OH)D was significantly lower in institutionalized women (56.9 [SD = 23.9] nmol/l) compared with noninstitutionalized women (63.2 [SD = 22.0] nmol/l; p < 0.0001). In institutionalized women (without vitamin D supplements), the prevalence of 25(OH)D inadequacy was 10.4, 41.2, 80.3 and 84.2% when considering cutoffs of 80, 75, 50 and 30 nmol/l, respectively. In the control group, the prevalence was 2.7, 22.9, 74.4 and 81.7%, respectively. The prevalence of vitamin D inadequacy was significantly higher in institutionalized women when considering the 75, 50 and 30 nmol/l cutoffs but not when considering the 80 nmol/l cutoff. This study highlights a high prevalence of vitamin D inadequacy in institutionalized, osteoporotic women. Compared with age-matched osteoporotic controls, the prevalence of severe vitamin D inadequacy was substantially more important in institutionalized women. We believe that a greater awareness of the importance of vitamin D inadequacy is needed in order to address this public health problem. [less ▲]

Detailed reference viewed: 57 (12 ULg)
Full Text
Peer Reviewed
See detailEffects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier, Pierre; Roux, C.; Ortolani, S. et al

in Osteoporosis International (2009), 20

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33 ... [more ▼]

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. RESULTS: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups. CONCLUSION: In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women. [less ▲]

Detailed reference viewed: 48 (11 ULg)
Full Text
Peer Reviewed
See detailAn unusual interference in parathormone assay caused by anti-goat IgG: a case report.
Cavalier, Etienne ULg; Delanaye, Pierre ULg; Carlisi, Ignazia ULg et al

in Clinical Chemistry & Laboratory Medicine (2009), 47(1), 118

Detailed reference viewed: 38 (9 ULg)
Full Text
Peer Reviewed
See detailIntérêt des anticorps monoclonaux dans le laboratoire d'analyses biomédicales
Mistretta, Virginie ULg; Cavalier, Etienne ULg; Collette, Julien ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 257-263

Detailed reference viewed: 49 (7 ULg)
Full Text
Peer Reviewed
See detailProduction des anticorps monoclonaux
Mistretta, Virginie ULg; Cavalier, Etienne ULg; Collette, Julien ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 248-252

Detailed reference viewed: 64 (9 ULg)
Full Text
Peer Reviewed
See detailAssessment of determinants for osteoporosis in elderly men.
Scholtissen, Sophie ULg; Guillemin, F.; Bruyère, Olivier ULg et al

in Osteoporosis International (2009), 20(7), 1157-66

SUMMARY: The aim of this cross-sectional study was to determine and quantify some determinants associated to low bone mineral density (BMD) in elderly men. This study showed that ageing, a lower body mass ... [more ▼]

SUMMARY: The aim of this cross-sectional study was to determine and quantify some determinants associated to low bone mineral density (BMD) in elderly men. This study showed that ageing, a lower body mass index (BMI), a higher blood level of C-terminal cross-linking telopeptides of type I collagen (CTX-1), family history of osteoporosis, and/or fracture and prior fracture were associated with bone mineral density. INTRODUCTION: Our aims were to identify some determinants associated to low bone mineral density in men and to develop a simple algorithm to predict osteoporosis. METHODS: A sample of 1,004 men aged 60 years and older was recruited. Biometrical, serological, clinical, and lifestyle determinants were collected. Univariate, multivariate, and logistic regression analyses were performed. Receiver operating characteristic analysis was used to assess the discriminant performance of the algorithm. RESULTS: In the multiple regression analysis, only age, BMI, CTX-1, and family history of osteoporosis and/or fracture were able to predict the femoral neck T-score. When running the procedure with the total hip T-score, prior fracture also appeared to be significant. With the lumbar spine T-score, only age, BMI, and CTX-1 were retained. The best algorithm was based on age, BMI, family history, and CTX-1. A cut-off point of 0.25 yielded a sensibility of 78%, a specificity of 59% with an area under the curve of 0.73 in the development and validation cohorts. CONCLUSION: Ageing, a lower BMI, higher CTX-1, family history, and prior fracture were associated with T-score. Our algorithm is a simple approach to identify men at risk for osteoporosis. [less ▲]

Detailed reference viewed: 70 (7 ULg)
Full Text
Peer Reviewed
See detailDéficit en vitamine D chez les femmes françaises ostéoporotiques et ostéopéniques
DeCock, Caroline; Bruyère, Olivier ULg; Collette, Julien ULg et al

in Revue du Rhumatisme (2008), 75

Objectif. – Des études antérieures ont démontré qu’un faible taux sanguin de vitamineD peut entraîner un hyperparathyroïdisme secondaire, qui augmente la fragilité osseuse et, de ce fait, le risque de ... [more ▼]

Objectif. – Des études antérieures ont démontré qu’un faible taux sanguin de vitamineD peut entraîner un hyperparathyroïdisme secondaire, qui augmente la fragilité osseuse et, de ce fait, le risque de fractures, particulièrement chez les sujets âgés de plus de 50 ans. Le but de ce travail est d’évaluer le niveau d’insuffisance en vitamine D chez les femmes franc¸aises ménopausées. Méthodes. – Nous avons mesuré la vitamine D (25OHD) sérique chez 1292 femmes franc¸aises ménopausées ostéoporotiques ou ostéopéniques, âgées de 52 à 94 ans. Dans cette population, 26,5% des patientes consommaient un complément de vitamine D. Quatre valeurs seuil de 25OHD ont été retenues sur base des données de la littérature : 30, 50, 75 et 80 nmol/l (< 12, < 20, < 30 ou < 32 ng/ml). Résultats. – Le taux sérique moyen de 25OHD était de 51,54±26,14 nmol/l [∼20,62 (∼10,46) ng/ml]. Trois cent quarante-trois patientes recevaient une supplémentation en vitamine D, associée ou non à du calcium. Celles-ci présentaient une concentration sérique moyenne de 25OHD supérieure à celle des non-consommatrices [65,09 nmol/l (∼26,04 ng/ml) versus 46,63 nmol/l (∼18, 65 ng/ml) ; p < 0,001]. Chez les patientes non supplémentées en vitamine D, le taux de prévalence de l’insuffisance en vitamineD était de 27,3 ; 54,1 ; 89,9 et 93,2% selon qu’on utilisait les seuils de 30, 50, 75 ou 80 nmol/l (∼12, 20, 30 ou 32 ng/ml). Le niveau moyen de 25OHD variait également suivant la saison au cours de laquelle la mesure avait été effectuée (p < 0,001). Ainsi, la valeur moyenne la plus élevée a été observée en été [53,41 (18,79) nmol/l (∼21,36 (7,52) ng/ml)]. Conclusion. – Cette étude met en évidence une prévalence élevée de l’insuffisance en vitamineD chez les femmes franc¸aises ménopausées ostéoporotiques ou ostéopéniques. [less ▲]

Detailed reference viewed: 20 (4 ULg)